Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP10 in Pediatric and Adult Patients With C3 Glomerulopathy
NCT02302755Phase 1Withdrawn
- Sponsor
- University of Iowa
- Start
- Nov 2014
- Primary completion
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CDX-1135 in Complement 3 glomerulopathy (C3G), sponsored by University of Iowa. Primary endpoint: C3 serum measurements, serum C3 breakdown products, and/or alternative pathway (AP) complement activity at 2 years. Planned start Nov 2014; status: withdrawn.
02
Drugs
CDX-1135
03
Conditions
Complement 3 glomerulopathy (C3G)
Beyond the preview
Go deeper on NCT02302755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02302755.